Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

These companies have compelling long-term futures, but the coming decade could prove particularly exciting as each one comes into its own.

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

The mystery of how cancers build up resistance mechanisms and evade the treatments that should have destroyed them is a ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...